Significant Wednesday Options Trading: RKLB, EAT, MED
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Nov 05 2025
0mins
Source: NASDAQ.COM
Brinker International Options Activity: Brinker International, Inc. (EAT) experienced significant options trading with 12,346 contracts, primarily focused on the $100 strike put option expiring November 21, 2025, which saw 5,445 contracts traded.
Medifast Inc Options Activity: Medifast Inc (MED) also had notable options trading, with 1,190 contracts traded, particularly for the $10 strike call option expiring June 18, 2026, which accounted for 875 contracts.
Trading Volume Context: The options trading volumes for both companies represented a substantial percentage of their average daily trading volumes over the past month, with EAT at 75.1% and MED at 74.3%.
Further Information: For more details on available expirations for options related to RKLB, EAT, or MED, StockOptionsChannel.com can be visited.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy RKLB?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on RKLB
Wall Street analysts forecast RKLB stock price to rise
11 Analyst Rating
7 Buy
4 Hold
0 Sell
Moderate Buy
Current: 74.420
Low
63.00
Averages
86.89
High
120.00
Current: 74.420
Low
63.00
Averages
86.89
High
120.00
About RKLB
Rocket Lab Corporation is an end-to-end space company. The Company designs and manufactures small and medium-class rockets, spacecraft and spacecraft components, and related software and services to support the space economy. The Company delivers reliable launch services, satellite manufacture, spacecraft design services, spacecraft components, spacecraft manufacturing, and other spacecraft and on-orbit management solutions that make it easier to access space. Its Launch Services segment provides launch and launch-related services to customers on a dedicated mission or ride-share basis. Its Space Systems segment comprises the design and manufacture of spacecraft components and spacecraft program management services, space data applications, and mission operations. Its space systems solutions are the building blocks for spacecraft, which include composite structures, reaction wheels, star trackers, solar solutions, radios, separation systems, and command and control spacecraft software.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Rocket Lab Stock Surge Driven by Defense Sentiment
- Market Sentiment Recovery: Rocket Lab shares surged 6.37% to $74.33 amid a broader rally in aerospace and defense stocks, driven by rising tensions between the U.S. and Iran, reflecting a positive market sentiment towards defense sectors.
- Hypersonic Testing Initiative: The upcoming Cassowary Vex mission, scheduled for late February, marks Rocket Lab's fourth hypersonic test in six months, aimed at reducing costs and increasing testing frequency for the U.S. and allies, thereby enhancing its strategic position in defense.
- Technical Analysis: Currently, the stock is trading 4.1% below its 20-day simple moving average but 1.2% above its 50-day average, indicating mixed short-term momentum, suggesting traders should monitor potential shifts in market sentiment closely.
- Earnings Preview: Rocket Lab is set to report earnings on February 26, with an EPS estimate of a 9-cent loss and revenue forecast of $178.07 million, while analysts maintain a Buy rating, indicating strong confidence in the company's future performance.
See More
Rocket Lab Faces Critical Neutron Test Failure
- Test Failure Impact: Rocket Lab's Neutron test failure has led to a decline in stock prices, raising significant doubts about the feasibility of its 2026 timeline, which could undermine investor confidence and future funding capabilities.
- Potential Revenue Stream: Should Neutron succeed, Rocket Lab could unlock a massive new revenue stream, reshaping its long-term growth narrative in the space industry and attracting greater investor interest.
- Market Reaction: The stock price drop on February 9, 2026, reflects investor concerns regarding the company's future prospects, potentially leading to short-term capital outflows.
- Strategic Implications: This test failure not only affects the company's short-term stock performance but may also have profound implications for its long-term strategic planning, forcing management to reassess its technological roadmap and market positioning.
See More
Pentagon Invests $68 Million to Accelerate Hypersonic Technologies
- Hypersonic Technology Investment: The Pentagon's Joint Hypersonics Transition Office has awarded $68 million across six vendors to accelerate the development of next-generation technologies capable of exceeding Mach 5, significantly enhancing the U.S. competitive edge in hypersonic weaponry.
- Dark Eagle Deployment: The U.S. Army has begun fielding the Dark Eagle, the nation's first operational ground-launched hypersonic weapon, with delivery expected to complete in early 2026, marking a critical advancement in the U.S. hypersonic weapons program.
- Commercial-Aerospace Defense Intersection: Companies like Starfighters Space are gaining attention at the intersection of commercial aerospace and defense testing, with Starfighters recently completing wind tunnel tests for STARLAUNCH 1, validating its air-launched system design and strengthening its position in the hypersonic market.
- Investment Flow into Industry: Hypersonic testing companies are securing significant institutional investments to expand production capacity and flight cadence, indicating a rapidly growing market demand for hypersonic technologies and driving strategic developments for related firms.
See More
Pentagon Accelerates Hypersonic Technology Development with $68 Million Investment
- Funding Injection: The Pentagon's Joint Hypersonics Transition Office has awarded $68 million to six vendors to accelerate the development of next-generation technologies capable of exceeding Mach 5, significantly enhancing the U.S. competitive edge in hypersonic weaponry.
- Weapon Deployment: The U.S. Army has begun fielding the Dark Eagle hypersonic weapon, with deliveries expected to complete in early 2026, marking the first operational use of ground-launched hypersonic weapons in the U.S., which could transform future battlefield dynamics.
- Commercial and Defense Synergy: Companies like Starfighters Space are positioned at the intersection of commercial aerospace and defense testing, attracting substantial private capital to enhance production capacity and flight cadence, reflecting strong market demand for rapidly advancing hypersonic technologies.
- Testing Progress: Starfighters Space recently completed wind tunnel testing for STARLAUNCH 1, validating separation behavior at Mach 0.85 and Mach 1.3, with results showing strong alignment with computational fluid dynamics predictions, laying a solid foundation for subsequent flight testing.
See More
U.S. Defense Stocks Surge on Iran Military Action Speculation
- Defense Stocks Surge: U.S. defense stocks rose sharply as reports indicated the Trump administration is nearing potential military action against Iran, with the SPDR S&P Aerospace & Defense ETF (NYSE:XAR) gaining 2% and the Global X Defense Tech ETF (NYSE:SHLD) rising 2.7%, significantly outperforming the broader market and reflecting bullish sentiment in the defense sector.
- Military Presence Expands: The U.S. has significantly increased its military footprint in the Middle East, deploying two aircraft carriers, multiple warships, hundreds of fighter jets, and advanced air defense systems, indicating preparations for a sustained military campaign in response to escalating tensions.
- Prediction Markets Flash Warning: Betting-implied odds on Polymarket for a U.S. attack on Iran surged, with probabilities rising 8 percentage points to 20% by February 21, and a dramatic increase to 55% by March 15, highlighting growing market concerns over potential escalation in the region.
- Limited Diplomatic Progress: Diplomatic talks between U.S. and Iranian officials have shown limited progress, with Vice President JD Vance stating that diplomacy could reach its “natural end” if Iran fails to meet U.S. red lines related to its nuclear program, further intensifying market anxiety regarding the situation.
See More
Shopify's Earnings Cause Market Whiplash; Moderna's Vaccine Rejected by FDA
- Shopify Earnings Volatility: Shopify's stock surged 13% in pre-market trading before its fourth-quarter earnings report, but plummeted 6% by the end of the day after management's conference call raised concerns about future growth, particularly regarding the concept of 'agentic commerce' that unsettled investors.
- Strong Revenue Growth: The company reported a 31% year-over-year revenue growth, maintaining the same rate as last year, with merchandise volume through its platform increasing by 29%, indicating ongoing expansion in the e-commerce sector; however, the missed EPS expectations led to a negative market reaction.
- Moderna Vaccine Approval Setback: The FDA's refusal to review Moderna's new flu vaccine marks the second regulatory challenge within a year, potentially jeopardizing the company's future MRNA technology developments, particularly for vaccines targeting cancer and rare diseases.
- Increased Cash Flow Pressure: Moderna faces significant cash burn, relying on revenue from COVID vaccines to fund its R&D; the FDA's rejection may force the company to reassess its development strategy in the current regulatory climate.
See More
Rocket Lab Stock Surge Driven by Defense Sentiment
- Market Sentiment Recovery: Rocket Lab shares surged 6.37% to $74.33 amid a broader rally in aerospace and defense stocks, driven by rising tensions between the U.S. and Iran, reflecting a positive market sentiment towards defense sectors.
- Hypersonic Testing Initiative: The upcoming Cassowary Vex mission, scheduled for late February, marks Rocket Lab's fourth hypersonic test in six months, aimed at reducing costs and increasing testing frequency for the U.S. and allies, thereby enhancing its strategic position in defense.
- Technical Analysis: Currently, the stock is trading 4.1% below its 20-day simple moving average but 1.2% above its 50-day average, indicating mixed short-term momentum, suggesting traders should monitor potential shifts in market sentiment closely.
- Earnings Preview: Rocket Lab is set to report earnings on February 26, with an EPS estimate of a 9-cent loss and revenue forecast of $178.07 million, while analysts maintain a Buy rating, indicating strong confidence in the company's future performance.
See More
Rocket Lab Faces Critical Neutron Test Failure
- Test Failure Impact: Rocket Lab's Neutron test failure has led to a decline in stock prices, raising significant doubts about the feasibility of its 2026 timeline, which could undermine investor confidence and future funding capabilities.
- Potential Revenue Stream: Should Neutron succeed, Rocket Lab could unlock a massive new revenue stream, reshaping its long-term growth narrative in the space industry and attracting greater investor interest.
- Market Reaction: The stock price drop on February 9, 2026, reflects investor concerns regarding the company's future prospects, potentially leading to short-term capital outflows.
- Strategic Implications: This test failure not only affects the company's short-term stock performance but may also have profound implications for its long-term strategic planning, forcing management to reassess its technological roadmap and market positioning.
See More
Pentagon Invests $68 Million to Accelerate Hypersonic Technologies
- Hypersonic Technology Investment: The Pentagon's Joint Hypersonics Transition Office has awarded $68 million across six vendors to accelerate the development of next-generation technologies capable of exceeding Mach 5, significantly enhancing the U.S. competitive edge in hypersonic weaponry.
- Dark Eagle Deployment: The U.S. Army has begun fielding the Dark Eagle, the nation's first operational ground-launched hypersonic weapon, with delivery expected to complete in early 2026, marking a critical advancement in the U.S. hypersonic weapons program.
- Commercial-Aerospace Defense Intersection: Companies like Starfighters Space are gaining attention at the intersection of commercial aerospace and defense testing, with Starfighters recently completing wind tunnel tests for STARLAUNCH 1, validating its air-launched system design and strengthening its position in the hypersonic market.
- Investment Flow into Industry: Hypersonic testing companies are securing significant institutional investments to expand production capacity and flight cadence, indicating a rapidly growing market demand for hypersonic technologies and driving strategic developments for related firms.
See More
Pentagon Accelerates Hypersonic Technology Development with $68 Million Investment
- Funding Injection: The Pentagon's Joint Hypersonics Transition Office has awarded $68 million to six vendors to accelerate the development of next-generation technologies capable of exceeding Mach 5, significantly enhancing the U.S. competitive edge in hypersonic weaponry.
- Weapon Deployment: The U.S. Army has begun fielding the Dark Eagle hypersonic weapon, with deliveries expected to complete in early 2026, marking the first operational use of ground-launched hypersonic weapons in the U.S., which could transform future battlefield dynamics.
- Commercial and Defense Synergy: Companies like Starfighters Space are positioned at the intersection of commercial aerospace and defense testing, attracting substantial private capital to enhance production capacity and flight cadence, reflecting strong market demand for rapidly advancing hypersonic technologies.
- Testing Progress: Starfighters Space recently completed wind tunnel testing for STARLAUNCH 1, validating separation behavior at Mach 0.85 and Mach 1.3, with results showing strong alignment with computational fluid dynamics predictions, laying a solid foundation for subsequent flight testing.
See More
U.S. Defense Stocks Surge on Iran Military Action Speculation
- Defense Stocks Surge: U.S. defense stocks rose sharply as reports indicated the Trump administration is nearing potential military action against Iran, with the SPDR S&P Aerospace & Defense ETF (NYSE:XAR) gaining 2% and the Global X Defense Tech ETF (NYSE:SHLD) rising 2.7%, significantly outperforming the broader market and reflecting bullish sentiment in the defense sector.
- Military Presence Expands: The U.S. has significantly increased its military footprint in the Middle East, deploying two aircraft carriers, multiple warships, hundreds of fighter jets, and advanced air defense systems, indicating preparations for a sustained military campaign in response to escalating tensions.
- Prediction Markets Flash Warning: Betting-implied odds on Polymarket for a U.S. attack on Iran surged, with probabilities rising 8 percentage points to 20% by February 21, and a dramatic increase to 55% by March 15, highlighting growing market concerns over potential escalation in the region.
- Limited Diplomatic Progress: Diplomatic talks between U.S. and Iranian officials have shown limited progress, with Vice President JD Vance stating that diplomacy could reach its “natural end” if Iran fails to meet U.S. red lines related to its nuclear program, further intensifying market anxiety regarding the situation.
See More
Shopify's Earnings Cause Market Whiplash; Moderna's Vaccine Rejected by FDA
- Shopify Earnings Volatility: Shopify's stock surged 13% in pre-market trading before its fourth-quarter earnings report, but plummeted 6% by the end of the day after management's conference call raised concerns about future growth, particularly regarding the concept of 'agentic commerce' that unsettled investors.
- Strong Revenue Growth: The company reported a 31% year-over-year revenue growth, maintaining the same rate as last year, with merchandise volume through its platform increasing by 29%, indicating ongoing expansion in the e-commerce sector; however, the missed EPS expectations led to a negative market reaction.
- Moderna Vaccine Approval Setback: The FDA's refusal to review Moderna's new flu vaccine marks the second regulatory challenge within a year, potentially jeopardizing the company's future MRNA technology developments, particularly for vaccines targeting cancer and rare diseases.
- Increased Cash Flow Pressure: Moderna faces significant cash burn, relying on revenue from COVID vaccines to fund its R&D; the FDA's rejection may force the company to reassess its development strategy in the current regulatory climate.
See More
